Fortress Biotech (FBIO) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
XBiotech (XBIT) has outperformed Fortress Biotech (FBIO) over the past year, losing 18.2% versus a loss of 28.2%. Over five years, XBIT leads with a -83.3% price change compared with -95.5% for FBIO. Fortress Biotech is the larger company by market cap ($69.7 million vs $67.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | XBIT |
|---|---|---|
| Share price | $2.09 | $2.20 |
| Market cap | $69.70M | $67.07M |
| 1-day change | +2.45% | +0.46% |
| YTD return | -42.90% | -7.95% |
| 1-year return | -28.18% | -18.22% |
| 5-year return | -95.48% | -83.35% |
| P/E ratio (TTM) | 0.76 | — |
| Forward P/E | — | 16.92 |
| EPS (TTM) | $2.76 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.53 | $3.44 |
| 52-week low | $2.00 | $2.09 |
| Distance from 52-week high | -53.86% | -36.05% |
| Analyst consensus | none | — |
| Avg. price target upside | +139.23% | — |
| Average volume | 495.05K | 39.91K |
| Shares outstanding | 33.35M | 30.49M |
| Employees | 78 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
FBIO vs XBIT FAQ
Which is bigger, Fortress Biotech or XBiotech?
Fortress Biotech (FBIO) is larger, with a market capitalization of $69.70M compared with $67.07M for XBiotech (XBIT).
Which stock has performed better over the past year, FBIO or XBIT?
XBIT returned -18.22% over the past 12 months, compared with -28.18% for FBIO (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.